epiClinicalA fictional CRO

epiClinical is fictional. It is a portfolio demonstration by Adam Daniels. Its studies, sponsors, sites and enrolment figures are synthetic. The evidence behind its assumptions is real, and every number says how far it can be trusted.

EPI-214, Phase III. Recruiting

Heart failure with reduced ejection fraction

CTS-209 added to standard care in heart failure with reduced ejection fraction. Sponsor: Contoso Pharmaceuticals (fictional), Cardiovascular.

Five leading KPIs warn whether recruitment will reach its target, with the screening funnel and the corrective actions that have evidence behind them.

KPIs at a glance

Data to September 30th 2026. Each measure links to its chart below.

Will the plan work?

Feasibility stretch

41.5% of site capacity

On course Competing trials: A few

Sites open against plan

120 of 120 planned

On course The plan spreads each country's sites over its start-up window

First site open to first patient

0.5 months

On course Alert at 2.3 months

Is recruitment on course?

Enrolment against plan

472 of 517 expected

On course Patients randomised against the plan

Site rate against expectation

×0.93 of expected

On course All sites pooled

Will the plan work?

The plan needs 120 sites, 41.5% of what its countries can supply, against a few competing trials. That leaves room to add sites if recruitment falls behind.

Sites are opening on schedule

Sites openNumber, by month, against the plan spread over each country's start-up window

Show data
Sites open: planned and actual, by month
MonthPlannedActual
Sep 202300
Dec 202300
Mar 20241721
Jun 20246266
Sep 20249898
Dec 2024113111
Mar 2025120120
Jun 2025120120
Sep 2025120120
Dec 2025120120
Mar 2026120120
Jun 2026120120
Sep 2026120120
Oct 2026120120

Sources: epiClinical synthetic sites; start-up windows from the planner parameters (D25)

Overdue for a first patient: 10.8% of open sites

Open sites by countryMonths from activation to first patient; hollow dots have none yet; orange marks a wait longer than nine in ten similar sites, or none randomised despite three or more expected

Show data
Months from activation to first patient, by site
SiteCountryMonths to first patientFlagged
214-US-01, San DiegoUnited States24.5No
214-US-02, Los AngelesUnited States2.4No
214-US-03, BaltimoreUnited States2.0No
214-US-04, AtlantaUnited States12.3No
214-US-05, BostonUnited StatesNone yet, 29.9 months openNo
214-US-06, New YorkUnited States7.8No
214-US-07, DenverUnited StatesNone yet, 27.7 months openNo
214-US-08, MiamiUnited States1.8No
214-US-09, NashvilleUnited States3.0No
214-US-10, ClevelandUnited StatesNone yet, 29.1 months openYes
214-US-11, Salt Lake CityUnited States2.6No
214-US-12, DallasUnited States10.6No
214-US-13, SeattleUnited States12.7No
214-US-14, PhoenixUnited States7.0No
214-US-15, MinneapolisUnited States18.9No
214-US-16, CharlotteUnited StatesNone yet, 29.7 months openNo
214-US-17, ChicagoUnited StatesNone yet, 32.3 months openYes
214-US-18, PhiladelphiaUnited StatesNone yet, 27.4 months openYes
214-US-19, PittsburghUnited States19.7No
214-US-20, HoustonUnited States0.0No
214-US-21, San DiegoUnited States0.9No
214-US-22, Los AngelesUnited StatesNone yet, 30.9 months openNo
214-US-23, BaltimoreUnited StatesNone yet, 28.1 months openYes
214-US-24, AtlantaUnited States20.4No
214-US-25, BostonUnited States11.8No
214-US-26, New YorkUnited States1.9No
214-US-27, DenverUnited States5.8No
214-US-28, MiamiUnited States3.0No
214-US-29, NashvilleUnited StatesNone yet, 27.8 months openNo
214-US-30, ClevelandUnited StatesNone yet, 32.1 months openNo
214-US-31, Salt Lake CityUnited States17.0No
214-US-32, DallasUnited States3.0No
214-US-33, SeattleUnited States2.8No
214-US-34, PhoenixUnited States20.1No
214-US-35, MinneapolisUnited States0.8No
214-US-36, CharlotteUnited States3.0No
214-US-37, ChicagoUnited StatesNone yet, 28.9 months openYes
214-US-38, PhiladelphiaUnited StatesNone yet, 27.8 months openNo
214-US-39, PittsburghUnited States14.2No
214-US-40, HoustonUnited States0.2No
214-UK-01, NottinghamUnited Kingdom1.0No
214-UK-02, EdinburghUnited Kingdom12.6No
214-UK-03, LeedsUnited Kingdom10.3No
214-UK-04, SheffieldUnited Kingdom5.1No
214-UK-05, LondonUnited Kingdom0.5No
214-UK-06, NewcastleUnited Kingdom0.7No
214-UK-07, BristolUnited KingdomNone yet, 27.0 months openNo
214-UK-08, LiverpoolUnited Kingdom4.7No
214-UK-09, OxfordUnited Kingdom5.0No
214-UK-10, CardiffUnited Kingdom5.6No
214-UK-11, CambridgeUnited Kingdom2.5No
214-UK-12, ManchesterUnited Kingdom9.4No
214-UK-13, SouthamptonUnited Kingdom5.7No
214-UK-14, BirminghamUnited KingdomNone yet, 31.5 months openYes
214-UK-15, GlasgowUnited Kingdom0.9No
214-ES-01, ZaragozaSpain10.5No
214-ES-02, PamplonaSpain10.2No
214-ES-03, SalamancaSpainNone yet, 25.6 months openNo
214-ES-04, BilbaoSpain0.0No
214-ES-05, MurciaSpain4.3No
214-ES-06, OviedoSpain3.8No
214-ES-07, ValenciaSpain4.8No
214-ES-08, SevilleSpain6.7No
214-ES-09, CórdobaSpain9.7No
214-ES-10, Santiago de CompostelaSpain4.3No
214-ES-11, GranadaSpain1.0No
214-ES-12, AlicanteSpain24.9No
214-ES-13, MadridSpain2.3No
214-ES-14, MálagaSpainNone yet, 26.2 months openYes
214-ES-15, BarcelonaSpain13.5No
214-ES-16, ZaragozaSpain28.2No
214-ES-17, PamplonaSpain1.8No
214-ES-18, SalamancaSpain3.8No
214-ES-19, BilbaoSpain2.5No
214-ES-20, MurciaSpain3.0No
214-PL-01, RzeszówPoland0.8No
214-PL-02, ZamośćPoland11.3No
214-PL-03, ŁódźPoland0.4No
214-PL-04, KrakówPoland7.0No
214-PL-05, WarsawPoland0.0No
214-PL-06, BydgoszczPoland5.0No
214-PL-07, PoznańPoland1.2No
214-PL-08, LublinPoland10.4No
214-PL-09, BiałystokPoland6.9No
214-PL-10, SzczecinPoland0.0No
214-PL-11, GdańskPoland0.6No
214-PL-12, OlsztynPoland1.2No
214-PL-13, KatowicePolandNone yet, 20.0 months openYes
214-PL-14, WrocławPoland0.6No
214-PL-15, RzeszówPolandNone yet, 20.3 months openNo
214-PL-16, ZamośćPoland0.4No
214-PL-17, ŁódźPoland0.3No
214-PL-18, KrakówPoland1.4No
214-PL-19, WarsawPoland2.8No
214-PL-20, BydgoszczPoland7.6No
214-TR-01, DiyarbakırTurkeyNone yet, 30.3 months openNo
214-TR-02, AdanaTurkeyNone yet, 26.0 months openYes
214-TR-03, AnkaraTurkey16.0No
214-TR-04, İzmirTurkeyNone yet, 28.6 months openYes
214-TR-05, MalatyaTurkey5.8No
214-TR-06, AntalyaTurkeyNone yet, 30.6 months openYes
214-TR-07, BursaTurkey14.7No
214-TR-08, AntakyaTurkey3.2No
214-TR-09, KayseriTurkey10.6No
214-TR-10, GaziantepTurkey20.7No
214-IN-01, DelhiIndia8.7No
214-IN-02, HyderabadIndia0.3No
214-IN-03, KochiIndia4.5No
214-IN-04, ChennaiIndia1.3No
214-IN-05, NagpurIndia14.0No
214-IN-06, AhmedabadIndia3.4No
214-IN-07, LucknowIndiaNone yet, 29.5 months openYes
214-IN-08, PuneIndia6.9No
214-IN-09, ChandigarhIndia0.9No
214-IN-10, BengaluruIndia13.0No
214-IN-11, VelloreIndiaNone yet, 25.1 months openNo
214-IN-12, KolkataIndia4.2No
214-IN-13, BhubaneswarIndia14.4No
214-IN-14, JaipurIndiaNone yet, 28.6 months openYes
214-IN-15, MumbaiIndia0.1No

Source: epiClinical synthetic sites. A slow site can wait months for its first patient by design, so each is judged against its own expected rate. At study level, a first patient more than about 70 days after the first site opened predicted slow accrual (MD Anderson, 4,269 trials). That alert, 2.3 months, drives the scorecard. It is a cut-off from historical data, not a standard.

Is recruitment on course?

Recruitment is keeping pace

Patients randomisedCumulative, against the count the plan expects from each country's rate and opening window

Show data
Patients randomised: planned and actual, by month
MonthPlannedActual
Sep 202300
Dec 202300
Mar 202425
Jun 20241820
Sep 20245242
Dec 202410089
Mar 2025155147
Jun 2025212194
Sep 2025270242
Dec 2025327292
Mar 2026384352
Jun 2026441400
Sep 2026498456
Oct 2026517472

Sources: epiClinical synthetic sites; plan from the planner. Studies under 60% of target at the planned end rarely recovered in NCI data (review note 02).

Which sites are behind their expectation?

Patients randomised as a share of those expectedEach dot a site, against the patients it was expected to recruit since it opened

Limits
Show data
Each site: patients expected to date, patients randomised and how far it is from its expectation
SiteCountryExpectedRandomisedObserved ÷ expectedJudgement
214-US-01, San DiegoUnited States3.71×0.271Within normal variation
214-US-02, Los AngelesUnited States3.52×0.567Within normal variation
214-US-03, BaltimoreUnited States3.14×1.296Within normal variation
214-US-04, AtlantaUnited States3.11×0.321Within normal variation
214-US-05, BostonUnited States1.90×0Within normal variation
214-US-06, New YorkUnited States5.12×0.392Within normal variation
214-US-07, DenverUnited States1.30×0Within normal variation
214-US-08, MiamiUnited States4.92×0.404Within normal variation
214-US-09, NashvilleUnited States4.18×1.939Within normal variation
214-US-10, ClevelandUnited States3.70×0Within normal variation
214-US-11, Salt Lake CityUnited States2.24×1.845Within normal variation
214-US-12, DallasUnited States3.05×1.692Within normal variation
214-US-13, SeattleUnited States5.02×0.403Within normal variation
214-US-14, PhoenixUnited States4.52×0.444Within normal variation
214-US-15, MinneapolisUnited States1.91×0.522Within normal variation
214-US-16, CharlotteUnited States1.40×0Within normal variation
214-US-17, ChicagoUnited States3.80×0Within normal variation
214-US-18, PhiladelphiaUnited States4.30×0Within normal variation
214-US-19, PittsburghUnited States5.01×0.201Within normal variation
214-US-20, HoustonUnited States4.78×1.715Within normal variation
214-US-21, San DiegoUnited States4.17×1.715Within normal variation
214-US-22, Los AngelesUnited States2.90×0Within normal variation
214-US-23, BaltimoreUnited States3.70×0Within normal variation
214-US-24, AtlantaUnited States2.31×0.442Within normal variation
214-US-25, BostonUnited States3.81×0.262Within normal variation
214-US-26, New YorkUnited States6.513×2.001Within normal variation
214-US-27, DenverUnited States4.95×1.011Within normal variation
214-US-28, MiamiUnited States3.58×2.301Within normal variation
214-US-29, NashvilleUnited States2.60×0Within normal variation
214-US-30, ClevelandUnited States2.00×0Within normal variation
214-US-31, Salt Lake CityUnited States2.32×0.867Within normal variation
214-US-32, DallasUnited States4.54×0.888Within normal variation
214-US-33, SeattleUnited States2.43×1.253Within normal variation
214-US-34, PhoenixUnited States4.91×0.204Within normal variation
214-US-35, MinneapolisUnited States4.87×1.462Within normal variation
214-US-36, CharlotteUnited States3.45×1.483Within normal variation
214-US-37, ChicagoUnited States3.10×0Within normal variation
214-US-38, PhiladelphiaUnited States3.00×0Within normal variation
214-US-39, PittsburghUnited States4.41×0.228Within normal variation
214-US-40, HoustonUnited States1.84×2.212Within normal variation
214-UK-01, NottinghamUnited Kingdom3.44×1.16Within normal variation
214-UK-02, EdinburghUnited Kingdom4.22×0.481Within normal variation
214-UK-03, LeedsUnited Kingdom2.83×1.07Within normal variation
214-UK-04, SheffieldUnited Kingdom3.99×2.28Within normal variation
214-UK-05, LondonUnited Kingdom5.67×1.248Within normal variation
214-UK-06, NewcastleUnited Kingdom4.54×0.897Within normal variation
214-UK-07, BristolUnited Kingdom2.90×0Within normal variation
214-UK-08, LiverpoolUnited Kingdom4.63×0.652Within normal variation
214-UK-09, OxfordUnited Kingdom3.32×0.613Within normal variation
214-UK-10, CardiffUnited Kingdom4.06×1.493Within normal variation
214-UK-11, CambridgeUnited Kingdom1.82×1.131Within normal variation
214-UK-12, ManchesterUnited Kingdom4.14×0.968Within normal variation
214-UK-13, SouthamptonUnited Kingdom4.55×1.121Within normal variation
214-UK-14, BirminghamUnited Kingdom4.50×0Within normal variation
214-UK-15, GlasgowUnited Kingdom3.96×1.53Within normal variation
214-ES-01, ZaragozaSpain2.45×2.126Within normal variation
214-ES-02, PamplonaSpain4.12×0.482Within normal variation
214-ES-03, SalamancaSpain2.20×0Within normal variation
214-ES-04, BilbaoSpain3.111×3.578Within normal variation
214-ES-05, MurciaSpain3.16×1.947Within normal variation
214-ES-06, OviedoSpain3.34×1.207Within normal variation
214-ES-07, ValenciaSpain5.32×0.38Within normal variation
214-ES-08, SevilleSpain4.96×1.223Within normal variation
214-ES-09, CórdobaSpain4.13×0.738Within normal variation
214-ES-10, Santiago de CompostelaSpain6.58×1.225Within normal variation
214-ES-11, GranadaSpain5.56×1.086Within normal variation
214-ES-12, AlicanteSpain3.81×0.265Within normal variation
214-ES-13, MadridSpain3.34×1.23Within normal variation
214-ES-14, MálagaSpain3.30×0Within normal variation
214-ES-15, BarcelonaSpain5.94×0.681Within normal variation
214-ES-16, ZaragozaSpain4.81×0.207Within normal variation
214-ES-17, PamplonaSpain4.611×2.398Within normal variation
214-ES-18, SalamancaSpain8.05×0.623Within normal variation
214-ES-19, BilbaoSpain3.11×0.317Within normal variation
214-ES-20, MurciaSpain6.54×0.619Within normal variation
214-PL-01, RzeszówPoland5.16×1.186Within normal variation
214-PL-02, ZamośćPoland3.33×0.917Within normal variation
214-PL-03, ŁódźPoland6.113×2.116Within normal variation
214-PL-04, KrakówPoland5.22×0.385Within normal variation
214-PL-05, WarsawPoland3.67×1.968Within normal variation
214-PL-06, BydgoszczPoland5.05×1.006Within normal variation
214-PL-07, PoznańPoland2.810×3.576Within normal variation
214-PL-08, LublinPoland6.93×0.436Within normal variation
214-PL-09, BiałystokPoland6.33×0.477Within normal variation
214-PL-10, SzczecinPoland8.931×3.5Within normal variation
214-PL-11, GdańskPoland4.48×1.81Within normal variation
214-PL-12, OlsztynPoland7.316×2.203Within normal variation
214-PL-13, KatowicePoland5.90×0Within normal variation
214-PL-14, WrocławPoland8.713×1.495Within normal variation
214-PL-15, RzeszówPoland2.70×0Within normal variation
214-PL-16, ZamośćPoland3.03×0.992Within normal variation
214-PL-17, ŁódźPoland7.02×0.286Within normal variation
214-PL-18, KrakówPoland4.62×0.439Within normal variation
214-PL-19, WarsawPoland2.93×1.019Within normal variation
214-PL-20, BydgoszczPoland6.93×0.432Within normal variation
214-TR-01, DiyarbakırTurkey2.50×0Within normal variation
214-TR-02, AdanaTurkey3.30×0Within normal variation
214-TR-03, AnkaraTurkey5.02×0.404Within normal variation
214-TR-04, İzmirTurkey6.70×0Within normal variation
214-TR-05, MalatyaTurkey3.64×1.106Within normal variation
214-TR-06, AntalyaTurkey3.30×0Within normal variation
214-TR-07, BursaTurkey4.44×0.909Within normal variation
214-TR-08, AntakyaTurkey3.69×2.489Within normal variation
214-TR-09, KayseriTurkey7.14×0.565Within normal variation
214-TR-10, GaziantepTurkey3.21×0.309Within normal variation
214-IN-01, DelhiIndia3.92×0.51Within normal variation
214-IN-02, HyderabadIndia3.96×1.553Within normal variation
214-IN-03, KochiIndia6.26×0.974Within normal variation
214-IN-04, ChennaiIndia5.014×2.824Within normal variation
214-IN-05, NagpurIndia3.63×0.834Within normal variation
214-IN-06, AhmedabadIndia9.34×0.429Within normal variation
214-IN-07, LucknowIndia4.10×0Within normal variation
214-IN-08, PuneIndia3.82×0.525Within normal variation
214-IN-09, ChandigarhIndia8.96×0.678Within normal variation
214-IN-10, BengaluruIndia5.32×0.379Within normal variation
214-IN-11, VelloreIndia1.70×0Within normal variation
214-IN-12, KolkataIndia3.05×1.677Within normal variation
214-IN-13, BhubaneswarIndia5.74×0.7Within normal variation
214-IN-14, JaipurIndia5.30×0Within normal variation
214-IN-15, MumbaiIndia4.115×3.646Within normal variation

Source: epiClinical synthetic sites. Allowing for site spread (coefficient of variation 0.9), a site expected to recruit a handful of patients can recruit none and still be within normal variation. Poisson-only limits flag far more sites.

Pooled, no country or region is outside its range; the United States is furthest behind at ×0.74

Sites grouped by country and flagged regionPatients randomised as a share of those expected; the bar is where an ordinary group of that size would land

Show data
Each group: sites, patients randomised against expected, and the range ordinary groups of that size fall in
GroupSitesRandomisedExpectedObserved ÷ expectedOrdinary rangeJudgement
United States40105141.0×0.745×0.688 to ×1.362Within normal variation
United Kingdom155758.0×0.983×0.531 to ×1.593Within normal variation
Spain208487.7×0.958×0.583 to ×1.513Within normal variation
Poland20133106.4×1.25×0.59 to ×1.505Within normal variation
Turkey102442.7×0.562×0.44 to ×1.752Within normal variation
India156973.7×0.936×0.527 to ×1.603Within normal variation
2023 earthquake province51416.3×0.86×0.264 to ×2.101Within normal variation
Belarus border region136.3×0.477×0 to ×3.599Within normal variation
Syria border region2106.8×1.46×0.023 to ×2.846Within normal variation
Ukraine border region51520.9×0.717×0.265 to ×2.126Within normal variation

Source: epiClinical synthetic sites

Where patients are lost before randomisation

Benchmarks for each step from referral to randomisation. Screen failure explains where patients are lost; on its own it does not predict whether a study reaches its target.

StepTypical conversionSource
Trial available at the patient's centre (cancer care)44.4% (100% minus 55.6% with no trial available)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible, among patients with a trial available (cancer care, derived)about 52% ((14.8 + 8.1) / 44.4). Note: the often-quoted 78.5% appears to be 100% minus 21.5%, a misreading because 21.5% is a share of all patientsUnger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Eligible among screened (primary care trials)median 83% (IQR 40% to 100%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Eligible among screened (knee osteoarthritis trials)median 71.9%Koog et al., Archives of Rheumatology, https://archivesofrheumatology.org/full-text/650
Approached among eligible (one oncology trial)91%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Agreed among those offered a trial (cancer trials, 35 studies)about 55% (55.0% treatment, 55.3% cancer control)Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155
Agreed among approached (one oncology trial)40%Lewis 2020, Trials, https://doi.org/10.1186/s13063-020-04559-w
Consented and randomised among eligible (388 NIHR trials)median 72% (IQR 50% to 88%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Enrolled among eligible (primary care trials)median 74% (IQR 49% to 92%)Jones 2009, BMC Family Practice, https://doi.org/10.1186/1471-2296-10-5
Enrolled among all cancer patients (end to end)8.1% (15.9% academic, 7% community centres)Unger 2019, JNCI, https://doi.org/10.1093/jnci/djy221
Screen failure after consent (oncology, one LMIC centre, 15 RCTs)51% failed (49% randomised); main causes inclusion criteria not met 54.9%, declined treatment 22.2%Parekh 2022, ecancermedicalscience, https://doi.org/10.3332/ecancer.2022.1476
Screen failure after consent (prodromal Alzheimer's, industry source)76% to 80% in two trials, against a typical 25% to 30% (grade D, not peer-reviewed)Worldwide Clinical Trials 2017 blog, https://www.worldwide.com/blog/2017/10/unique-4-step-approach-limits-high-screen-failure-in-alzheimers-disease-research-part-1/
Retained with valid primary outcome among randomised (388 NIHR trials)median 88% (IQR 80% to 97%)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Recruitment rate (388 NIHR trials)median 0.95 participants per centre per month (IQR 0.42 to 2.60)Jacques 2022, BMJ Open, https://doi.org/10.1136/bmjopen-2021-059230
Consent to randomisation intervalno published benchmark found; protocol-specific, label any default Illustrativenone found

What works when a measure goes red

The evidence review's 16 corrective and preventive actions (CAPAs), strongest evidence first. Grade A is strong, D means no quantitative evidence was found.

ActionGradeAnswersEffect
Telephone follow-up of people who did not reply to an invitationAlow enrolment rate; low response to invitation lettersRisk difference +6 percentage points (95% CI 3 to 9), high certainty, clearest where baseline recruitment is low (under about 10% of those invited). Earlier version: RR 1.66 (95% CI 1.03 to 2.46), 2 studies, 1,058 participants.
Open rather than blinded placebo design (design stage only)Apredicted low enrolment at feasibility; high refusal linked to placeboRisk difference +10 percentage points (95% CI 7 to 13), high certainty.
Monetary thank-you for returning follow-up questionnairesBhigh drop-out; missing primary outcome data; low questionnaire returnPostal: RR 1.18 (95% CI 1.09 to 1.28); higher vs lower value RR 1.12 (1.04 to 1.22); electronic, offered on receipt, RR 1.25 (1.14 to 1.38). 2021 update: incentive vs usual follow-up RR 1.20 (1.06 to 1.36), 3 studies, 3,166 participants, low certainty.
Pre-notification before follow-up, with reward or reminderBhigh drop-out; low questionnaire returnMonetary reward with reminder or pre-notification improved retention, moderate certainty; no pooled number extracted. PROMETHEUS SWATs found pre-notification effective; no effect size in the abstract.
Reduce follow-up burden (home self-sampling, no extra diaries)Bhigh drop-out; missed visits; missing primary outcome dataSelf-sampling kits improved retention, moderate certainty (no pooled number extracted). Adding a diary reduced retention: RR 0.97 (95% CI 0.96 to 0.98), 2 studies, 9,906 participants, moderate certainty.
Opt-out contact for potential participantsClow enrolment rate; few patients approachedRR 1.39 (95% CI 1.06 to 1.84), but from a single study of 152 people; not among the high-certainty findings of the 2018 update.
Personalised text messages for follow-upChigh drop-out; low questionnaire returnMixed: PROMETHEUS found personalised texts improved questionnaire response (no effect size in abstract); Cochrane pooled electronic reminders RR 1.01 (95% CI 0.95 to 1.09), 3 studies, 790 participants, low certainty.
Broaden eligibility criteria by protocol amendmentChigh screen failure; low eligible-to-screened ratio; low enrolment rateModelled in advanced NSCLC real-world data (61,094 patients): relaxing restrictive criteria more than doubled the eligible pool on average, with hazard ratio change of about 0.05 and no rise in toxicity-related discontinuation. No prospective evidence of the effect on actual randomisations. Amendments: median direct cost about $141k (phase II) and $535k (phase III), about 3 months added.
Participant payments or reimbursementClow consent among approached; low enrolment rateMixed in two RCTs: smoking-cessation trial consent 21.8% ($0) vs 35.9% ($200) vs 47.1% ($500); ambulation trial no effect (45.4%, 48.1%, 43.0%). No evidence of undue inducement in these low-risk trials.
Add decentralised elementsClow enrolment rate; high drop-out; patients living far from sitesOf 13 studies, 10 or 11 reported better recruitment with decentralised methods, mostly without head-to-head comparison; a 2022 systematic review found insufficient comparable data to say whether decentralised trials recruit or retain better.
Screening-log review to find the leaking funnel stageCany red recruitment KPI; high screen failure; low consent among approachedNo quantitative evidence that logs raise recruitment. In one oncology trial, logs showed 91% of eligible patients approached but 40% agreeing, pointing at the consent conversation; logs were incomplete (47% returned; 28% of enrolled patients missing).
Close or replace non-enrolling sitesDsites with zero enrolment; low site productivity; slow activationNo quantitative evidence on the effect of closing sites. Context only: 11% of activated sites enrol no one and 37% under-enrol (Tufts CSDD 2012 data).
Add sites or countriesDlow enrolment rate; forecast misses last patient in dateNo quantitative evidence on adding sites as a rescue. Diminishing returns follow from activation lag and site variability rather than from a measured effect. Context: median 0.95 participants per centre per month (IQR 0.42 to 2.60) in NIHR trials.
Increase site or investigator paymentsDlow site productivity; low enrolment rateNo quantitative evidence for patient recruitment; a 2005 systematic review found almost no experimental evidence and raised conflict-of-interest concerns. One RCT of paying doctors concerned recruiting doctors as study subjects, not patient recruitment.
Central campaigns, recruitment vendors and referral networksDfew patients identified; no trial available at local centres; low enrolment rateNo quantitative evidence found in peer-reviewed comparative studies within this review. Context: in cancer care, no trial was available at the patient's centre for 55.6% of patients, which referral networks aim to address.
Site re-training and extra site support visitsDlow site productivity; low approach rate; high screen failure from avoidable errorsNo quantitative evidence found; the 2021 Cochrane retention review found only two studies targeting site staff.